Abstract
The interaction between Cryptococcus neoformans and the host system is a consummate process, on account of the multiple components involved in its traversal of the blood-brain barrier (BBB). It is possible that this yeast pathogen may use different mechanisms of invasion under different physiological or pathological conditions. Understanding these mechanisms of encroachment can explicate the route of invasion, which may provide us with an indication for identifying the potential drug target sites. Current C. neoformans management still relies on the anti-fungal reagents, such as amphotericin B, fluconazole, or fluorocytosine. However, potential treatments on BBB, e.g., flurofamide and simvastatin, are emerging. This review summarizes the possible routes for C. neoformans traversal of the BBB, current regimens for C. neoformans, and potential new targets for treatments.
Keywords: Amphotericin B, brain invasion, blood-brain barrier, C. neoformans, lipid rafts, simvasatatin.
Anti-Infective Agents
Title:The Blood-Brain Barrier: Targeting in the Pathogenesis of C. neoformans Meningitis and Drug Discovery
Volume: 11 Issue: 2
Author(s): Hsiang-Kuang Tseng, Sheng-He Huang, Gregory Shackleford and Ambrose Jong
Affiliation:
Keywords: Amphotericin B, brain invasion, blood-brain barrier, C. neoformans, lipid rafts, simvasatatin.
Abstract: The interaction between Cryptococcus neoformans and the host system is a consummate process, on account of the multiple components involved in its traversal of the blood-brain barrier (BBB). It is possible that this yeast pathogen may use different mechanisms of invasion under different physiological or pathological conditions. Understanding these mechanisms of encroachment can explicate the route of invasion, which may provide us with an indication for identifying the potential drug target sites. Current C. neoformans management still relies on the anti-fungal reagents, such as amphotericin B, fluconazole, or fluorocytosine. However, potential treatments on BBB, e.g., flurofamide and simvastatin, are emerging. This review summarizes the possible routes for C. neoformans traversal of the BBB, current regimens for C. neoformans, and potential new targets for treatments.
Export Options
About this article
Cite this article as:
Tseng Hsiang-Kuang, Huang Sheng-He, Shackleford Gregory and Jong Ambrose, The Blood-Brain Barrier: Targeting in the Pathogenesis of C. neoformans Meningitis and Drug Discovery, Anti-Infective Agents 2013; 11 (2) . https://dx.doi.org/10.2174/2211352511311020005
DOI https://dx.doi.org/10.2174/2211352511311020005 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Perspectives of Infections in Cardiovascular Disease
Current Cardiology Reviews Meet the Editorial Board Member
Anti-Infective Agents Molecular Approach to Targeted Therapy for Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Tuberculosis Detection from Chest Radiographs: A Comprehensive Survey on Computer-Aided Diagnosis Techniques
Current Medical Imaging Role of Microglia in the Pathogenesis of Sepsis-Associated Encephalopathy
CNS & Neurological Disorders - Drug Targets Serum Tryptophan, Tryptophan Catabolites and Brain-derived Neurotrophic Factor in Subgroups of Youngsters with Autism Spectrum Disorders
CNS & Neurological Disorders - Drug Targets Methods for Providing Therapeutic Agents to Treat Damaged Spiral Ganglion Neurons
Current Drug Targets - CNS & Neurological Disorders Targeted Vascular Drug Delivery in Cerebral Cancer
Current Pharmaceutical Design Current Challenges and Updates on the Therapy of Fungal Infections
Current Topics in Medicinal Chemistry PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Synthesis of the Alzheimer Drug Posiphen into its Primary Metabolic Products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their Inhibition of Amyloid Precursor Protein, α -Synuclein Synthesis, Interleukin-1β Release, and Cholinergic Action.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Management of Spasticity in Progressive Multiple Sclerosis: Efficacy of Repeated Intrathecal Triamcinolone Acetonide Administration
Current Pharmaceutical Design IL-17A and Multiple Sclerosis: Signaling Pathways, Producing Cells and Target Cells in the Central Nervous System
Current Drug Targets Nanotechnology Applications for Diffuse Intrinsic Pontine Glioma
Current Neuropharmacology The Clinical and Immunological Features of Patients with Primary Antibody Deficiencies
Endocrine, Metabolic & Immune Disorders - Drug Targets Otitis Media: Epidemiology and Management
Infectious Disorders - Drug Targets Recent Patents on Epilepsy Genetics
Recent Patents on DNA & Gene Sequences Ganglioside GM3 and Its Role in Cancer
Current Medicinal Chemistry Strategies to Create a Regenerating Environment for the Injured Spinal Cord
Current Pharmaceutical Design Linezolid in Children: Recent Patents and Advances
Recent Patents on Anti-Infective Drug Discovery